Diabetes has traditionally been subtyped as type 1 (autoimmune diabetes), which typically presents in childhood or adolescence or type 2, which typically presents in adulthood and is often accompanied by insulin resistance and obesity. However, there exist many subtypes of diabetes, not currently considered when initiating treatment. Current practice dictates the treatment of type 1 Diabetes with insulin and type 2 Diabetes with primarily oral antihyperglycemic agents as well as injectable GLP1 therapies. However, the subclassification of diabetes and the presence or absence of comorbid conditions can help further individualized care and prevent diabetic complications. The surge in use of continuous glucose monitors can further help individualize treatment.  

Newer technologies such as continuous glucose monitoring and advanced insulin pump options with algorithms allowing for immediate insulin titration, when linked together, have become available for the treatment, primarily of type 1 diabetes. These technologies have not been widely explored in the treatment of other forms of diabetes, including type 2 diabetes, gestational diabetes and their subtypes. Discussion regarding the use of these technologies to improve not just overall glycemic control, but also time in target glucose range and avoidance of hypoglycemia will advance practice to allow for more stringent diabetes control. Additionally, discussion of inpatient glycemic management with these devices would allow for further understanding of how such devices can help providers transition care more seamlessly from inpatient to outpatient settings.